Company intelligence / Profile preview

Kamada Ltd.

Ownership: Public · KMDA
Employees: ~374
Development stage: Commercial

Overview

Kamada has multiple FDA-approved commercial products including GLASSIA, KEDRAB, CYTOGAM, HEPAGAM B, VARIZIG, and WINRHO SDF. The company is also conducting the InnovAATe clinical trial, a Phase 3 pivotal trial for inhaled AAT for AATD treatment.

Therapeutic areas: HematologyImmunologyRare DiseasesInfectious Diseases
Modalities: Plasma-derived protein therapeuticsRecombinant proteinsHyperimmune IgG
Industry: Biotech

Drug pipeline

5 assets

rho(d) immune globulin (Panamerican Biotecnologia)

4 more assets in the full pipeline.

Request access →

Partnerships

Baxalta/ShireChiesiKedrionPari Pharma

Financials

Market cap: $478.3M
Total revenue: $54.9M
Enterprise value: $420M

Beyond the preview

Go deeper on Kamada Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kamada Ltd..

Explore the full profile